Prospectus, August 20, 1975

$70,000 BUDGET HANDLED BY PC STUDENT GOVERNMENT; PC news in brief: Garfield Press........, History…..............; PC activity day schedule: Aug. 26; The Hartline; IOC to meet September 2; The Kaleidoscope; Student paper needs help; Political? Run in stugo election; Student govenrment establishes new goals; Student elections Sept. 9-10; Freddy 3 years old: Fast Freddy\u27s football forecast; IM offers competition; Insurance available; Games Of September 6https://spark.parkland.edu/prospectus_1975/1008/thumbnail.jp

The Lantern Vol. 55, No. 1, Fall 1988

• The Third Grade Gorilla • Friend, I Am Not Yet A Poet • Twisted • The Final Journey • Ritu Miltonis • Hearthside • The Ogre • O Indestructible Everlasting • December 1, 1988 • Our Church • Louise • Gazebo For Learned Women • Hanging Mirror • Of Football and Flashlights • The Ragged Brown Peasant • Judgement of the Serpent • Sidewalk Wars • I Guess That\u27s Why I Went Awayhttps://digitalcommons.ursinus.edu/lantern/1133/thumbnail.jp

The Lantern Vol. 55, No. 1, Fall 1988

• The Third Grade Gorilla • Friend, I Am Not Yet A Poet • Twisted • The Final Journey • Ritu Miltonis • Hearthside • The Ogre • O Indestructible Everlasting • December 1, 1988 • Our Church • Louise • Gazebo For Learned Women • Hanging Mirror • Of Football and Flashlights • The Ragged Brown Peasant • Judgement of the Serpent • Sidewalk Wars • I Guess That\u27s Why I Went Awayhttps://digitalcommons.ursinus.edu/lantern/1133/thumbnail.jp

A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future

Improved influenza vaccines are urgently needed to reduce the burden of seasonal influenza and to ensure a rapid and effective public-health response to future influenza pandemics. The Influenza Vaccines Research and Development (R&D) Roadmap (IVR) was created, through an extensive international stakeholder engagement process, to promote influenza vaccine R&D. The roadmap covers a 10-year timeframe and is organized into six sections: virology; immunology; vaccinology for seasonal influenza vaccines; vaccinology for universal influenza vaccines; animal and human influenza virus infection models; and policy, finance, and regulation. Each section identifies barriers, gaps, strategic goals, milestones, and additional R&D priorities germane to that area. The roadmap includes 113 specific R&D milestones, 37 of which have been designated high priority by the IVR expert taskforce. This report summarizes the major issues and priority areas of research outlined in the IVR. By identifying the key issues and steps to address them, the roadmap not only encourages research aimed at new solutions, but also provides guidance on the use of innovative tools to drive breakthroughs in influenza vaccine R&D.publishedVersio

Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine

Despite rapid technical progress and demonstrable effectiveness for some types of diagnosis and therapy, much remains to be learned about clinical genome and exome sequencing (CGES) and its role within the practice of medicine. The Clinical Sequencing Exploratory Research (CSER) consortium includes 18 extramural research projects, one National Human Genome Research Institute (NHGRI) intramural project, and a coordinating center funded by the NHGRI and National Cancer Institute. The consortium is exploring analytic and clinical validity and utility, as well as the ethical, legal, and social implications of sequencing via multidisciplinary approaches; it has thus far recruited 5,577 participants across a spectrum of symptomatic and healthy children and adults by utilizing both germline and cancer sequencing. The CSER consortium is analyzing data and creating publically available procedures and tools related to participant preferences and consent, variant classification, disclosure and management of primary and secondary findings, health outcomes, and integration with electronic health records. Future research directions will refine measures of clinical utility of CGES in both germline and somatic testing, evaluate the use of CGES for screening in healthy individuals, explore the penetrance of pathogenic variants through extensive phenotyping, reduce discordances in public databases of genes and variants, examine social and ethnic disparities in the provision of genomics services, explore regulatory issues, and estimate the value and downstream costs of sequencing. The CSER consortium has established a shared community of research sites by using diverse approaches to pursue the evidence-based development of best practices in genomic medicine